Furthermore, the percentage of CD8+ T cells in the tumor lesions of DTT-neoAg immunized mice was 11.48 ± 0.35%, a 2-fold increase as compared with that of the PBS-treated mice (5.25 ± 0.41%) (Figure 6E). This evidence concerns the gene CD8A and neoplasm.